Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 17, 2026

Establishment and Analysis of Tumor Slice Explants As a Prerequisite for Diagnostic Testing
11:00

Establishment and Analysis of Tumor Slice Explants As a Prerequisite for Diagnostic Testing

Published on: November 29, 2018

Histologic subtype in NSCLC: does it matter?

Giovanni Selvaggi1, Giorgio V Scagliotti

  • 1Department of Clinical and Biological Sciences, University of Turin, Thoracic Oncology Unit, San Luigi Hospital, Orbassano, Turin, Italy.

Oncology (Williston Park, N.Y.)
|January 2, 2010
PubMed
Summary

Platinum-based chemotherapy is standard for advanced non-small-cell lung cancer (NSCLC). New treatments like bevacizumab and EGFR inhibitors, along with histology, are personalizing NSCLC therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to 'Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes' [JTO Clinical and Research Reports 6 (2025) 100914].

JTO clinical and research reports·2026
Same author

Unraveling lung cancer dynamics: a new metabolic signature improving the prediction of recurrence in resected lung adenocarcinoma.

Journal of translational medicine·2026
Same author

Biomarker Testing and Patterns of Treatment in Patients with NSCLC: An International Association for The Study of Lung Cancer Analysis of American Society of Clinical Oncology CancerLinQ Discovery Data.

JTO clinical and research reports·2026
Same author

Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes.

JTO clinical and research reports·2025
Same author

Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations-Genomic Features Associated with Response to Therapy.

European urology oncology·2025
Same author

Natural History and Real-World Treatment Outcomes for Patients With NSCLC Having <i>EGFR</i> Exon 20 Insertion Mutation: An International Association for the Study of Lung Cancer-American Society of Clinical Oncology CancerLinQ Study.

JTO clinical and research reports·2024

Area of Science:

  • Oncology
  • Pulmonology
  • Medical Genetics

Background:

  • Platinum-based doublet chemotherapy is the standard first-line treatment for advanced non-small-cell lung cancer (NSCLC) in patients with good performance status.
  • Recent studies have challenged this standard, showing benefits with bevacizumab addition and targeted therapies like gefitinib/erlotinib for EGFR-mutation-positive NSCLC.
  • Histology is emerging as a crucial predictive factor in advanced NSCLC treatment selection.

Purpose of the Study:

  • To evaluate the impact of histology on treatment response and survival in advanced non-small-cell lung cancer (NSCLC).
  • To explore the role of thymidylate synthase expression in differential treatment effects across NSCLC histotypes.
  • To emphasize the importance of accurate pathologic subclassification for personalized NSCLC therapy.

Related Experiment Videos

Last Updated: Jun 17, 2026

Establishment and Analysis of Tumor Slice Explants As a Prerequisite for Diagnostic Testing
11:00

Establishment and Analysis of Tumor Slice Explants As a Prerequisite for Diagnostic Testing

Published on: November 29, 2018

Main Methods:

  • Analysis of prospective data from a phase III study subgroup and retrospective reviews.
  • Investigating the interaction between treatment, histology, and outcomes (response/survival) in NSCLC.
  • Examining thymidylate synthase expression differences among lung cancer histotypes.

Main Results:

  • A significant interaction between treatment by histology was observed, particularly in non-squamous NSCLCs treated with pemetrexed compared to squamous cell carcinoma (SCC).
  • Thymidylate synthase expression was found to be lower in adenocarcinoma and higher in SCC and small-cell lung cancer.
  • These findings suggest differential efficacy of certain chemotherapies based on tumor histology.

Conclusions:

  • Histology is a critical factor influencing treatment outcomes in advanced non-small-cell lung cancer (NSCLC).
  • Accurate pathologic subclassification from adequate biopsy tissue is essential for selecting optimal, individualized chemotherapy regimens.
  • The shift towards molecularly based approaches necessitates precise diagnostic pathology for effective NSCLC management.